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Lineagehe transcription factor SOX9 to be required for the maintenance of multipotential
pancreatic progenitor cells in the early embryonic pancreas. However, the association of pancreatic endocrine
defects with the Sox9-haploinsufﬁciency syndrome campomelic dysplasia (CD) implies additional later roles
for Sox9 in endocrine development. Using short-term lineage tracing in mice, we demonstrate here that
SOX9 marks a pool of multipotential pancreatic progenitors throughout the window of major cell
differentiation. During mid-pancreogenesis, both endocrine and exocrine cells simultaneously arise from
the SOX9+ epithelial cords. Our analysis of mice with 50%-reduced Sox9 gene dosage in pancreatic
progenitors reveals endocrine-speciﬁc defects phenocopying CD. By birth, these mice display a speciﬁc
reduction in endocrine cell mass, while their exocrine compartment and total organ size is normal. The
decrease in endocrine cells is caused by reduced generation of endocrine progenitors from the SOX9+
epithelium. Conversely, formation of exocrine progenitors is insensitive to reduced Sox9 gene dosage, thus
explaining the normal organ size at birth. Our results show that not only is SOX9 required for the
maintenance of early pancreatic progenitors, but also governs their adoption of an endocrine fate. Our
ﬁndings therefore suggest that defective endocrine speciﬁcation might underlie the pancreatic phenotype of
individuals with CD.
Published by Elsevier Inc.IntroductionDuring embryonic development, all differentiated cells in the
vertebrate pancreas are generated from a common pool of multi-
potential pancreatic progenitor cells. Lineage-tracing studies in mice
have shown that progenitors marked by the transcription factors
PDX1 and PTF1a give rise to the acinar and ductal cells of the
exocrine pancreas as well as to the endocrine lineages of the islets
of Langerhans, including the insulin-producing β-cells, the gluca-
gon-producing α-cells, the somatostatin-producing δ-cells, and the
pancreatic polypeptide (PP)-producing cells (Gu et al., 2002;
Kawaguchi et al., 2002). With the initiation of the secondary
transition, which marks the onset of major endocrine and exocrine
cell differentiation around embryonic day (e) 13.5, PDX1 and PTF1a
become markers of mature pancreatic cell types. PDX1 expression
becomes restricted to insulin+ cells and newly-differentiated acinar
cells (Guz et al., 1995), while PTF1a becomes compartmentalized
within the acini (Krapp et al., 1996). Because neither PDX1 nor
PTF1a are exclusive progenitor cell markers throughout the duration
of pancreas development, it is still unclear whether multipotential
progenitor cells persist in the pancreas throughout its development.Stem Cell Program, University
nc.Endocrine cell differentiation is initiated by the transcription factor
NGN3, which marks a transient population of speciﬁed endocrine
progenitors throughout embryogenesis. Studies in mice have shown
that Ngn3 is both required and sufﬁcient to induce endocrine
differentiation (Gradwohl et al., 2000; Gu et al., 2002; Jensen et al.,
2000; Schwitzgebel et al., 2000). While endocrine-committed
progenitors can be found as early as e10.5, exocrine commitment
does not occur until around e14. PTF1a- and carboxypeptidase A-
(CPA-) expressing cells are initially multipotential, but later in
development exclusively mark committed exocrine progenitors that
reside in the tips of the branching pancreatic epithelium (Zhou et
al., 2007).
We have recently shown that the HMG box transcription factor
SOX9 is co-expressed with PDX1 in multipotential progenitors of the
undifferentiated pancreatic epithelium between e9 and e12.5. How-
ever, in contrast to PDX1, SOX9 is excluded from lineage-committed
progenitors and differentiated cells at the beginning of the secondary
transition (Seymour et al., 2007). During this time, SOX9 becomes
exclusively localized to the epithelial cords, which have been
suggested to harbor uncommitted progenitor cells (Fujitani et al.,
2006). Notably, in the epithelial cords, NGN3+ cells exist in an
intercalated arrangement amongst the SOX9+ cells, suggesting that
endocrine progenitors may arise from the SOX9+ cell population.
Postnatally, SOX9 expression becomes restricted to the ductal and
centroacinar cell compartment (Seymour et al., 2007), which has been
suggested to harbor endocrine-differentiation-competent progenitors
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raises the question of how long SOX9+ cells normally contribute to cell
neogenesis during pancreas development.
Through pancreas-speciﬁc Pdx1-Cre-mediated inactivation of
Sox9, we demonstrated that SOX9 controls the maintenance of
pancreatic progenitors by stimulating their proliferation, survival,
and persistence in an undifferentiated state (Seymour et al., 2007).
However, because the Pdx1-Cre transgene results in efﬁcient early
deletion of Sox9 and severe pancreatic hypoplasia by e11.5, our
analysis of SOX9-deﬁcient pancreata precluded the dissection of
possible additional roles of SOX9 during pancreatic cell differentia-
tion at later stages of development. Several pancreatic transcrip-
tion factors have been found to play distinct early and later roles
in pancreogenesis. For example, PDX1 initially promotes outgrowth
of the pancreatic anlagen (Jonsson et al., 1994), but subsequently
plays a role in maintaining proper β-cell function (Ahlgren et al.,
1998). Furthermore, Pdx1-haploinsufﬁciency is associated with
increased islet apoptosis in adult mice (Johnson et al., 2003),
suggesting that correct Pdx1 gene dosage is required for endocrine
cell maintenance. Likewise, Sox9 is a known haploinsufﬁcient
gene: in humans, heterozygosity for loss-of-function mutations in
Sox9 is associated with the semi-lethal skeletal malformation
syndrome campomelic dysplasia (CD) (Foster et al., 1994; Wagner
et al., 1994). Neonates with CD have recently been shown to
display pancreatic islet defects, including islet hypoplasia and
decreased expression of hormones and β-cell maturity markers
(Piper et al., 2002). Though the ﬁndings in individuals with CD
strongly suggest a role for Sox9 in islet cell development, the
mechanism underlying islet hypoplasia as a result of Sox9-
haploinsufﬁciency has yet to be identiﬁed.
In this study, we have examined whether the SOX9+ epithelial
cords serve as a reservoir of multipotential progenitors throughout
pancreatic development and whether Sox9 function is required to
initiate cell differentiation from this epithelium. Utilizing Sox9-eGFP
mice for short-term in vivo lineage tracing of SOX9+ cells, we show
that during mid-pancreogenesis the SOX9+ epithelium simulta-
neously gives rise to NGN3+ endocrine progenitors, the different
endocrine cell types and exocrine acinar cells. Our analysis is the
ﬁrst to demonstrate that a compartment of multipotential progeni-
tors persists after the secondary transition of pancreas develop-
ment. To further test whether Sox9 plays a role in pancreatic cell
differentiation, we analyzed pancreatic development in mice in
which Pdx1-Cre mediates deletion of a single Sox9ﬂox allele. Similar
to individuals with CD, such Sox9+/Δpan mice display a 50%
reduction in islet cell mass, while their pancreatic exocrine
compartment is unaffected. We show that the reduction in
endocrine cells results from a defect in the generation of sufﬁcient
endocrine progenitors, thus revealing a dosage-sensitive require-
ment for SOX9 in initiating endocrine fate.
Materials and methods
Mouse strains
Sox9-eGFP (Tg(Sox9-eGFP)209Gsat/Mmcd) mice (Gong et al.,
2003) were obtained from the MMRRC and were maintained on
a CD1 genetic background. Sox9+/Δpan embryos and Cre− littermate
controls were generated by crossing heterozygous males of the
Pdx1-Cre line (Gu et al., 2002) with homozygous females of the
Sox9-ﬂox line (Kist et al., 2002). The Sox9-ﬂox line was maintained
on a mixed FVB/N×C57Bl/6J genetic background. Mice were
maintained on a 12 h light–dark cycle and all protocols were
approved by the UC Irvine Institutional Animal Care and Use
Committee. Embryos were harvested from timed matings in which
noon of the day of vaginal plug appearance was considered as e0.5.
For BrdU labeling, pregnant females were injected i.p. with 50 μg/gbody weight of BrdU (Sigma) and embryos were harvested 1 h after
injection.
Histological analysis
Staining was performed on sections of whole embryos (e12.5),
dissected guts (e15.5), or isolated pancreata (e18.5). Length of ﬁxation
in 4% paraformaldehyde in PBS at 4 °C was determined empirically. For
frozen sections, tissues were cryoprotected in 30% sucrose in PBS,
embedded in O.C.T. (Sakura Finetek) and sections cut at 10 μm. For
parafﬁn sections, tissue was dehydrated in an increasing ethanol
series, cleared in xylene and embedded in Paraplast (Kendall):
sections were cut at 7 μm. H and E staining and immunoﬂuorescence
analysis of proteins was performed as described previously (Sander et
al., 1997). When required, antigen retrieval was performed in pH 6.0
citrate buffer followed by additional permeabilization in 0.15% Triton
X-100 in PBS. For detection of BrdU, DNAwas denatured with 2 M HCl
at 37 °C for 1 h and a M.O.M. Kit (Vector Labs) was used. For triple
staining, the M.O.M. Kit was used in conjunction with AMCA Avidin D
(Vector Labs). DBAwas stained for using biotinylated DBA (1:200) and
visualized with Texas Red Avidin (Vector Labs). TUNEL staining was
performed using the ApopTag Plus Peroxidase In Situ Apoptosis
Detection Kit (Chemicon). When necessary, nuclei were counter-
stained with DAPI (Sigma) at 0.1 μg/ml.
The following primary antibodies were used at the given
dilutions: rabbit anti-SOX9 (Stolt et al., 2003), 1:2000; rabbit anti-
SOX9 (Chemicon), 1:1000; guinea-pig anti-PDX1 (kindly provided by
C. V. E. Wright, Vanderbilt University, Nashville, TN), 1:10,000; rabbit
anti-PDX1, (kindly provided by H. Edlund, Umeå University, Sweden),
1:3000; rabbit anti-PTF1a (kindly provided by H. Edlund), 1:1000;
guinea-pig anti-NGN3 (Henseleit et al., 2005), 1:1000; guinea-pig
anti-NKX6.1 (Henseleit et al., 2005), 1:1000; rabbit anti-NKX6.1
(kindly provided by P. Serup, Hagedorn Research Institute, Gentofte,
Denmark), 1:10,000; rabbit anti-MAFA (Bethyl Labs), 1:1500; guinea-
pig anti-ISL1 (kindly provided by J. Ericson, Karolinska Institute,
Stockholm, Sweden), 1:5000; rabbit anti-HB9 (kindly provided by J.
H. Kehrl, NIH), 1:8000; rat anti-E-cadherin/uvomorulin (Sigma),
1:1000; guinea-pig anti-insulin (DAKO), 1:5000; mouse anti-insulin
(Sigma), 1:5000; mouse anti-glucagon (Sigma), 1:5000; goat anti-
ghrelin (Santa Cruz), 1:1000; mouse anti-somatostatin (P. Serup),
1:2000; rabbit anti-pancreatic polypeptide (DAKO), 1:2000; rabbit
anti-amylase (Sigma), 1:500; rabbit anti-carboxypeptidase A (Bio-
trend), 1:1000; rabbit anti-GLUT2 (Alpha Diagnostics), 1:200; rabbit
anti-PC1/3 (kindly provided by D. F. Steiner, University of Chicago,
IL), 1:2000; rabbit anti-IAPP/amylin (Peninsula), 1:2000; mouse anti-
GAPDH (Ambion), 1:100,000; and mouse anti-BrdU (Chemicon),
1:50.
For immunoﬂuorescence detection, the following goat-raised
secondary antibodies were used (all at 1:2000 dilution): Cy3-
conjugated anti-rabbit, anti-mouse, anti-guinea-pig or anti-goat,
Cy5-conjugated anti-rabbit or anti-mouse (all Jackson Labs, raised in
donkey); Alexa- (488 nm) conjugated anti-rabbit, anti-mouse, or anti-
guinea-pig (all Molecular Probes) and Alexa- (555 nm) conjugated
anti-mouse (Molecular Probes).
Specimens were viewed on a Zeiss Axioplan 2 microscope and 24-
bit TIFF images were acquired with a Zeiss AxioCam digital camera
driven by Zeiss AxioVision v. 3.1 software. Co-localization studies for
GFP, SOX9 and NGN3 in Sox9-eGFP mice were performed with a Zeiss
LSM510META laser scanning confocal microscope. Images were
processed with Adobe Photoshop 6.0. Cell counting and/or morpho-
metry was performed on every ﬁfth section through the early
embryonic pancreas from a minimum of three mutants and three
wild-type somite-matched littermates. Morphometry was conducted
using Image-Pro Plus v. 5.0.1 (Media Cybernetics). Relative pancreatic
areas of β-cells, α-cells and acini were calculated and cell mass
determined as described previously (Garofano et al., 1998).
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Islets were isolated by intra-ductal injection of Liberase (0.5 mg/
ml), puriﬁed on a Ficoll gradient and hand-picked under amicroscope.
RNA was isolated with the RNeasy Mini and Micro kit (Qiagen) and
treated with DNAse. Synthesis of cDNA was performed with the
Superscript III cDNA kit (Invitrogen). Q-PCR reactions were performed
in triplicate using the Sybr Green kit (Applied Biosystems). Listed 5′ to
3′, primer sequences were as follows: Glut2 forward: TCAGAAGA-
CAAGATCACCGGA and reverse: GCTGGTGTGACTGTAAGTGGG; MafA
forward: AGGAGGAGGTCATCCGACTGAT and reverse: CTTCTCGCTCT-
CCAGAATGTG; beta-actin forward: AACCCTAAGGCCAACCGTGAAAAG
and reverse: CAGGATGGCGTGAGGGAGAGC; GABA-A receptor intron 5
forward: AACACACACTGGCAGGACTGGCTAGC and reverse: CAATGG-
TAGGCTCACTCTGGGAGATGATA. Primers for the Neurog3 promoter
were designed as described (Lynn et al., 2007). The core PCR program
was 94 °C for 10 s, 60 °C for 10 s and 72 °C for 10 s for 39 cycles.
Analysis of the datawas performed using the comparativeΔCtmethod
(Livak and Schmittgen, 2001).
Chromatin immunoprecipitation (ChIP)
e15.5 pancreata (n=25) were dissected and ﬁxed at room tem-
perature with 1% formaldehyde for 10 min then were quenched with
125 mM glycine. Fixed pancreata were subsequently homogenized
using a pestle with cell lysis buffer and were stored in liquid
nitrogen until the day of use. The ChIP assay was performed as
described (Lynn et al., 2007). For each assay, 5 μg of rabbit anti-SOX9
antibody (Chemicon) or rabbit IgG (Santa Cruz) was used. Pulled-
down DNA was puriﬁed by phenol/chloroform/isoamyl alcohol-
extraction and the concentration was determined using a Nano-
Drop spectrophotometer.
Insulin and glucagon assays
Total protein was isolated from freshly-dissected e18.5 pan-
creata via overnight acid–ethanol extraction at 4 °C following
sonication. Total protein content of the supernatant was measured
by the Bradford assay (Bradford, 1976). Insulin and glucagon
content were assayed in supernatant and diluted to be in the
linear range of detection using Mercodia Ultrasensitive Mouse
Insulin ELISA (Alpco Diagnostics) and Rat Glucagon ELISA (Wako)
kits, respectively.
Western blots
Total protein was isolated from freshly-dissected e15.5 pancreata
(n=3 per genotype) into protein lysis buffer (10 mM Tris–HCl pH7.8;
150 mM NaCl; 1 mM EDTA; 1% Nonidet P40 and protease inhibitor
cocktail tablet [Roche]), sonicated for 3×15 s, and then incubated
on ice for 30 min. 1 mg of protein was loaded on an SDS-Page gel
and proteins subsequently transferred onto a nitrocellulose mem-
brane in transfer buffer (500 mM Glycine, 50 mM Tris–HCl, 0.01%
SDS and 20% methanol) at 200 V for 1 h. Membranes were: washed
in PBST (1×PBS, 0.1% Tween pH 7.4); blocked with 3% non-fat milk
for 1 h; incubated in primary antibody diluted in 1% BSA in PBST O/
N at 4 °C; washed with PBST and incubated with HRP-conjugated
secondary antibody for 1 h at RT. After washing, signal was
visualized using the ECL™ Western Blotting Analysis System
(Amersham/GE Healthcare). Protein expression levels were quanti-
ﬁed with ImageQuant v. 5.0.
Statistical analysis
Statistical signiﬁcance was determined by Student's t-test using
Minitab v. 15.Results
SOX9-expressing progenitors are multipotent giving rise to all pancreatic
cell lineages
In previous studies we have shown that in the embryonic pancreas
SOX9 is exclusively expressed in undifferentiated cells and absent
from endocrine progenitors as well as differentiated endocrine and
acinar cells (Seymour et al., 2007). To investigate whether Sox9-
expressing cells represent a population of multipotential progenitor
cells throughout embryogenesis, we conducted short-term lineage-
tracing studies based on the expression of green ﬂuorescent protein
(GFP).
To follow the fate of SOX9+ cells, we analyzed pancreata of Sox9-
eGFP (Tg(Sox9-EGFP)209Gsat/Mmcd) mice (Gong et al., 2003) at e10.5,
e15.5 and e18.5 as well as postnatally. In these transgenic mice,
expression of eGFP is controlled by a BAC containing 80 kb of 5′ and
140 kb of 3′ Sox9 regulatory sequences. Due to the protein stability of
GFP, cells will continue to express GFP for N24 h after the Sox9
promoter is no longer active (Li et al., 1998), thus allowing for short-
term tracing of progeny that have arisen from SOX9+ cells. To conﬁrm
that the half-life of GFP indeed exceeds that of SOX9 protein in the
developing pancreas, we cultured embryonic pancreatic anlagen from
Sox9-eGFP mice in the presence of the protein synthesis inhibitor
cycloheximide. After 12 h of culture, SOX9 protein was no longer
detected in the explant, while GFP was readily detectable (Suppl. Figs.
1A–C). This validates that Sox9-eGFP mice can be used for short-term
lineage tracing. To verify that the BAC transgene contains requisite
regulatory elements to target the Sox9-expressing domain, we
analyzed multiple tissues from Sox9-eGFP mice for co-localization of
SOX9 and GFP. In adult pancreas, which is characterized by low cell
turnover, the domains of SOX9 and GFP expression were identical
(Suppl. Fig. 1D). Likewise, a complete overlap of SOX9 and GFP
expression was observed in the adult cerebellum (Suppl. Fig. 1E).
These data show that the BAC transgene directs expression of GFP
exclusively to Sox9-expressing cells. The ﬁnding that the BAC
transgene faithfully recapitulates the domain of endogenous SOX9
expression is consistent with previous studies which have demon-
strated that the BAC transgene size renders them more resistant to
position effects than smaller transgenes (Giraldo and Montoliu, 2001;
Gong et al., 2003).
In contrast to the adult CNS, where cells are largely postmitotic, the
embryonic CNS is characterized by rapid neurogenesis from progeni-
tors, which are localized in the so-called ventricular zone in the
medial aspect of the neural tube. In Sox9-eGFP embryos, SOX9 protein
was exclusively detected in the ventricular zone, while GFP expression
was also seen in differentiated neurons of the adjacent mantle zone
(Suppl. Fig. 1F). The intensity of GFP signal in the neural tube
decreased from medial to lateral. The pattern of GFP intensity mirrors
the time that elapsed since the neuron has been generated, because
neurons arise from the progenitors in the ventricular zone and
subsequently begin migrating laterally into the mantle zone. The
pattern of GFP distribution in the neural tube of Sox9-eGFP mice
therefore validates the idea that the stability of GFP protein in cells
that no longer express Sox9 can be used for short-term lineage tracing.
As expected, virtually all SOX9+ cells in the pancreas also expressed
GFP throughout embryonic development (Figs. 1A, B, F, G). At e10.5,
when most pancreatic epithelial cells are still undifferentiated proge-
nitors, we observed almost complete overlap between the GFP+ and
SOX9+ domain (Fig. 1A–A”). Occasionally, cells expressing GFP but not
SOX9 were found (Fig. 1A’, A”). As these cells were also glucagon+, it is
likely that they represent early-differentiated cells that arose from a
SOX9+ progenitor. Notably, a small subpopulation of glucagon+ cells
also expressed SOX9 (Fig. 1A’). At e15.5, the pancreatic epithelium
comprises undifferentiated progenitors, as well as differentiated
endocrine and exocrine cells. At this stage, the GFP+ area was conﬁned
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developing acini (Fig. 1C). SOX9+/GFP+ cells at e15.5 marked the
epithelial cords (Fig. 1B), which have been speculated to be a com-
partment for uncommitted progenitors (Fujitani et al., 2006). Usingconfocal imaging of sections co-stained for SOX9 and NGN3, we
detected three different populations of cells: SOX9+/NGN3−, SOX9+/
NGN3+ and SOX9−/NGN3+ cells (Fig. 1B’). While previous studies by
others and us have suggested that only a small subset of NGN3+ cells
Table 1
Quantiﬁcation of NGN3+ Endocrine Progenitor Cells Expressing SOX9 Protein
Sox9 co-localization amongst NGN3+ population (% of total NGN3+ cells counted)
Sox9Hi Sox9Lo Sox9−
13.1±3.59 74.1±3.07 12.8±5.83
The average number of NGN3+ cells expressing high (Hi) levels, low (Lo) levels, or no
detectable SOX9 protein was determined on sections from e15.5 embryos after co-
immunoﬂuorescence detection of SOX9 and NGN3 and confocal microscopy (n=107
NGN3+ cells). The numbers shown represent the mean number±standard error of the
mean (SEM).
Fig. 2. A two-fold reduction in Sox9 gene dosage has no effect on organ size. (A)Western
blot of protein extracts frome15.5 pancreata (n=3) shows a 46% decrease in SOX9 in Sox9
heterozygous pancreatic mutants (Sox9+/Δpan) vs. wild-type (WT) littermates. At e18.5,
gross anatomy of the pancreas (demarcated bya red dashed line) in Sox9+/Δpanmice (C) is
undistinguishable from that of wild-type littermates (B). In concordance, body weight
(D) and pancreas wet weight (E) are equivalent in Sox9+/Δpan (n=19) and wild-type
(n=31) embryos at e18.5. (D, E) The values shown represent mean values±SEM
(standard error of the mean). (B, C) Scale bar=200 μm.
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analysis revealed a signiﬁcant fraction of NGN3+ cells with weak SOX9
immunoreactivity. Careful quantiﬁcation demonstrated that 74% of
NGN3+ cells also express low levels of SOX9 (Table 1). This suggests that
during endocrine differentiation cells might undergo the following
transition: SOX9+/NGN3−→SOX9+/NGN3+→SOX9−/NGN3+→SOX9−/
NGN3−/hormone+. Indeed, the observation that SOX9−/NGN3+/GFP+
cells are found in Sox9-eGFP mice (Fig. 1B’, B”) indicates that NGN3+
cells originate from SOX9+ progenitors. The ﬁnding that such a cell
population could still be detected at e17.5 (Fig. 1F’, F”) further suggests
that NGN3+ cells continue to arise from SOX9+ cells later in embryo-
genesis. To determine whether SOX9+ cells give rise to the different
endocrine lineages, we next assayed for co-expression of insulin and
glucagon togetherwith GFP in Sox9-eGFP embryos. In contrast to SOX9,
which is not co-expressed with endocrine hormones (Seymour et al.,
2007), we detected GFP in a large number of glucagon+ and insulin+
cells at both e15.5 (Fig. 1D) and e18.5 (Fig. 1 H). At e15.5, ∼90% of all
insulin+ cells also expressed GFP, while ∼65% insulin+ cells were found
to be GFP+ at e18.5. These ﬁndings imply that endocrine cells con-
tinuously arise from SOX9+ progenitors between∼e14 and e18. To fully
assess the developmental potential of SOX9+ progenitors at different
stages of development, we also determined whether GFP co-localizes
with the exocrine marker amylase. At e15.5, GFP was detected in acini
that are budding from the tips of the epithelial cords (Fig. 1E). At e18.5,
however, no co-localization between GFP and amylase was observed
(Fig. 1I), therefore suggesting that acinar cells arise from SOX9+
progenitors around ∼e14, but not in late embryogenesis. Together,
these results show that SOX9+ cells are multipotential and give rise to
the endocrine and exocrine lineages of the pancreas.
Gross pancreatic morphology is normal in Sox9+/Δpan mice
Next, we sought to determine whether SOX9 is important for the
differentiation of speciﬁc cell lineages in the pancreas. Studies in mice
and humans have shown that Sox9 is a dosage-sensitive gene. A
reduction in gene dosage by mutation of one Sox9 allele causes
Campomelic Dysplasia (CD) (Foster et al., 1994), a human syndrome
characterized by skeletal malformations, variable sex reversal, and
abnormalities of the pancreatic islets (Piper et al., 2002). Since the
severe early developmental defects of Sox9-deﬁcient pancreata
precluded an analysis of later roles for SOX9 in pancreatic cell
differentiation, we analyzed pancreatic development in mice inwhichFig. 1. Endocrine and exocrine cells originate from the SOX9+ epithelial cords. (A–A”) Simulta
analysis shows almost complete overlap of GFP and SOX9 expression in the dorsal pancreatic
occasional SOX9/glucagon coexpressing cells are detected (A’, arrow in inset). All glucagon+
for E-cadherin reveals that the GFP signal is restricted to the epithelial progenitor cords at e1
majority of the SOX9+/GFP+ cells do not express NGN3 (B, B’, yellow arrowheads), while a sma
NGN3+ cells shows no SOX9 expression but retains GFP label (B’, B”, white arrowheads), sugge
insulin (D, arrows) and glucagon (D, arrowheads) as well as amylase (E, arrows). Since SOX
lineages originate from SOX9+ cells. (F–F”) Simultaneous detection of SOX9, NGN3 and G
embryogenesis. Note the NGN3+/SOX9− cells that are GFP+ (F’, F”, arrowheads). The arrow (F’
SOX9 in the pancreatic ducts (G). GFP label continues to be seen in a proportion of insulin+ (H
GFP at e18.5 (I), suggesting that endocrine, but not exocrine cells, continue to arise from SOX9
B–B” and F–F”. INS, insulin; GLU, glucagon; AMY, amylase; E-CAD, E-cadherin. Scale bar=50Pdx1-Cre-mediated recombination inactivated one Sox9ﬂox allele early
during pancreas development (Sox9+/Δpan mice).
Using quantitative Western blot analysis of protein extracts
obtained from whole pancreata of Sox9+/Δpan and wild-type litter-
mates, we determined that conditional deletion of one Sox9 allele
resulted in a 46% reduction (n=3) of SOX9 protein in Sox9 hetero-
zygous mutant pancreata (Fig. 2A).
Sox9+/Δpan mice were fully viable and fertile and their appearance
was indistinguishable from that of wild-type littermates. In contrast to
homozygous Sox9Δpan/Δpan mice, the overall pancreatic size and
morphology appeared normal in Sox9+/Δpan mice (Figs. 2B, C).
Accordingly, body weight (Fig. 2D) and pancreas weight (Fig. 2E) of
Sox9+/Δpan embryos at e18.5 were no different from those of wild-type
littermates. Therefore, unlike Sox9 null mutations in the pancreas, a
50% reduction of Sox9 gene dosage does not affect gross pancreas
morphogenesis.
Islet size is reduced in Sox9+/Δpan mice
To determine whether reduced Sox9 gene dosage affects the
development of the different pancreatic cell types, we examined the
histology of Sox9+/Δpan pancreata. In H&E-stained pancreatic sections
from e18.5 embryos, the highly eosinophilic exocrine compartment
exhibited a similar appearance and size in both Sox9+/Δpan and Sox9+/+neous detection of SOX9, glucagon and GFP in Sox9-eGFPmice and subsequent confocal
bud at e10.5. While most glucagon+ cells do not express SOX9 (A’, arrowheads in inset),
cells express GFP (A”, arrow and arrowheads). Staining of sections from Sox9-eGFP mice
5.5 (C). (B–B”) Simultaneous detection of SOX9, NGN3 and GFP at e15.5 shows that the
ll proportion of the SOX9+ cells also express NGN3 (B’, white arrows). Notably, a subset of
sting that NGN3+ cells arise from the SOX9+ domain. Also, at e15.5, GFP co-localizes with
9 protein is absent from endocrine and exocrine cells at e15.5, this indicates that both
FP at e17.5 shows that NGN3+ cells continue to arise from SOX9+ progenitors late in
, F”) points to a cell that expresses SOX9, NGN3 and GFP. At e18.5, GFP co-localizes with
, arrows) and glucagon+ (H, arrowheads) cells. However, amylase+ cells no longer retain
+ progenitors until birth. Note that the SOX9 signal was digitally color-converted in A–A’,
μm in A–B and D–I; 100 μm in C.
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mice (purple, heavily nucleated cells in Fig. 3B) were reduced in size
compared with those of wild-type littermates (Fig. 3A). These ﬁndings
suggest that a 50% reduction of SOX9 levels selectively affects the
development of the endocrine compartment.Fig. 3. Sox9-haploinsufﬁciency leads to islet-speciﬁc hypoplasia. Hematoxylin and eosin (H&E
compared to wild-type (WT) pancreas (A). Numbers of insulin+ β-cells and glucagon+ α-cells
ductal compartments (G, H) of the exocrine pancreas, are indistinguishable between Sox9+/Δ
and β-cell mass in Sox9+/Δpan vs. control pancreata at e18.5, while the acinar cell mass, as ass
both total pancreatic insulin (J) and glucagon (K) in Sox9+/Δpan compared to wild-type pancre
INS, insulin; GLU, glucagon; AMY, amylase; DBA, Dolichos biﬂorus agglutinin; i, islet. (A–H) STo examine whether hormone-expressing cells form in Sox9
heterozygous mutant pancreata, we performed immunostaining for
insulin and glucagon as markers of β- and α-cells, respectively. The
islets of Sox9+/Δpan mice showed normal islet architecture with a core
of insulin+ cells surrounded by the four other endocrine cell types (Fig.) staining reveals signiﬁcant islet hypoplasia in Sox9heterozygousmutant (Sox9+/Δpan) (B)
are equally reduced in Sox9+/Δpan islets (C, D), while the amylase+ acinar (E, F) and DBA+
pan and wild-type pancreas. (I) Morphometry conﬁrms signiﬁcant reductions in both α-
essed by amylase+ tissue area, is unchanged (n=3). ELISAs verify signiﬁcant decreases in
ata (n=5). The values shown represent mean values±SEM (standard error of the mean).
cale bar=100 μm.
Fig. 4. Sox9-haploinsufﬁciency does not result in impaired terminal differentiation of
endocrine cells. Immunoﬂuorescence staining formarkers ofdifferentiatedendocrine cells,
including GLUT2, PC1/3, IAPP, MAFA, PDX1, NKX6.1, ISL1 and HB9 reveals all markers to be
equally expressed in insulin+ cells of Sox9 heterozygous mutant (Sox9+/Δpan) (E–H; M–P)
and wild-type (WT) (A–D; I–L) pancreata at e18.5. qRT-PCRs performed on pooled mRNA
from 200 isolated islets per genotype, conﬁrm that islet Glut2 and MafA mRNA levels are
similar in two 2-month-old Sox9+/Δpan and WT mice. The values shown represent mean
values±SEM (standard error of the mean) (n=3) (Q). (A–P) Scale bar=50 μm.
25P.A. Seymour et al. / Developmental Biology 323 (2008) 19–303D, data not shown). However, the overall numbers of endocrine cells
appeared to be reduced in Sox9 heterozygous mutant pancreata (Figs.
3C, D). These ﬁndings were further supported by morphometric
analyses, which revealed β- and α-cell mass to be 57% and 55%
reduced, respectively (Fig. 3I). Likewise, δ- and PP-cells, marked by
somatostatin and pancreatic polypeptide staining, respectively, and
ghrelin+ cells showed a similar decrease in numbers in Sox9+/Δpan
pancreata at e18.5 (Suppl. Fig. 2).To assess the extent of overall reduction in pancreatic insulin and
glucagon levels in Sox9+/Δpan mice, total pancreatic insulin and
glucagon content were assayed by ELISA from extracts of whole
e18.5 pancreata. In close concordance with the morphometric data,
total pancreatic insulinwas reduced by 44% in Sox9+/Δpanmice relative
to wild-type littermates (mean total pancreatic insulin=Sox9+/Δpan:
5.17±0.342 μg/mg total protein vs. Sox9+/ﬂox: 9.23±0.623 μg/mg total
protein; n=5; P=0.001) (Fig. 3J), while total pancreatic glucagon was
decreased by 34.9% (mean total pancreatic glucagon=Sox9+/Δpan:
9.51±0.832 ng/mg total protein vs. Sox9+/ﬂox: 14.6±1.06 ng/mg total
protein; n=5; P=0.007) (Fig. 3K).
In contrast to the endocrine compartment, acinar morphology and
proportional area representation (on the basis of amylase staining)
was normal in Sox9+/Δpan embryos at e18.5 (Figs. 3E, F, I). Likewise,
Dolichos biﬂorus agglutinin (DBA) staining revealed no difference in
the numbers and distribution of DBA+ cells between Sox9+/Δpan and
control pancreata (Figs. 3G, H). Notably, identical phenotypic changes
in the pancreas were observed in a mouse model of heterozygous
germline deletion for Sox9 as well as in mice, in which wild-type Sox9
mRNA levels are reduced as a consequence of aberrant splicing into
the neo cassette in intron 1 of Sox9 (unpublished mouse model, Ralf
Kist and Gerd Scherer) (Suppl. Fig. 3).
This analysis reveals a dosage-dependent requirement for SOX9 in
pancreatic development, speciﬁcally in the formation of the endocrine
lineages. The similar reduction of endocrine cell numbers and
hormone content suggests that each endocrine cell produces normal
amounts of hormone. To gain further insight into whether Sox9-
haploinsufﬁciency affects the terminal differentiation of endocrine
cells, we performed a comprehensive immunohistochemical analysis
for various islet markers.
Islets in Sox9+/Δpan embryos show normal expression of β-cell markers
Proper glucose sensing and insulin processing in β-cells requires
the expression of the glucose transporter GLUT2 and the insulin pro-
cessing enzyme prohormone convertase (PC), respectively. To deter-
mine whether β-cells in Sox9-haploinsufﬁcient pancreata express
these functionally important proteins, we performed co-immunoﬂuo-
rescence analysis for GLUT2 and PC1/3 in conjunction with insulin.
Expression of both GLUT2 (Figs. 4A, E) and PC1/3 (Figs. 4B, F) was,
however, maintained in Sox9+/Δpan islets. Likewise, β-cells in Sox9+/Δpan
mice expressed islet amyloid polypeptide (IAPP) (Figs. 4C, G), a protein
that is co-secreted with insulin.
Since proper β-cell differentiation has been shown to depend upon
the expression of numerous islet transcription factors, we next
assayed for their expression in β-cells of Sox9+/Δpan mice. Similar to
wild-type mice, islets from Sox9-haploinsufﬁcient mice expressed the
transcription factors MAFA (Figs. 4D, H), PDX1 (Figs. 4I, M) NKX6.1
(Figs. 4J, N), ISL1 (Figs. 4K, O), and HB9 (Figs. 4L, P). Quantiﬁcation of
mRNA levels for Glut2 andMafa in isolated islets andWestern blots for
GLUT2 in embryonic pancreata further conﬁrmed that β-cells express
normal amounts of these factors (Fig. 4Q, data not shown).
Taken together, these ﬁndings suggest that decreased Sox9 gene
dosage has no impact on the terminal differentiation of pancreatic
β-cells. This implies that Sox9 may have an earlier role in endocrine
cell genesis, possibly in the release of sufﬁcient numbers of endo-
crine progenitors from the SOX9+ multipotential progenitor cell
compartment.
Sox9+/Δpan embryos exhibit a two-fold reduction in the numbers of
endocrine progenitors
If SOX9 is indeed required for the speciﬁcation of endocrine pro-
genitors, the expression of the endocrine progenitor cell marker
NGN3 should be reduced in Sox9+/Δpan pancreata. Consistent with
this notion, immunoﬂuorescence analysis for NGN3 and subsequent
Fig. 5. Endocrine progenitors are two-fold reduced in Sox9 heterozygous mutant pancreata. Numbers of NGN3+ endocrine progenitor cells are 50% reduced in the Sox9 heterozygous
mutant (Sox9+/Δpan) compared to wild-type (WT) pancreas (n=3) both as a proportion of total (DAPI+) pancreatic epithelial cells at e12.5 (A–C; pancreatic epithelium highlighted by
yellow dashed line in A, B) and per squaremillimeter of pancreas tissue at e15.5 (D–F). Chromatin immunoprecipitation studies of cross-linked chromatin from dissected pancreata at
e15.5 with anti-SOX9 antiserum show that SOX9 occupies sequences in the Neurog3 promoter. Three fragments, as previously described by Lynn et al. 2007, were ampliﬁed by PCR
from either input DNA, DNA precipitated with IgG or anti-SOX9 antiserum. Sequences from the GABA-A receptor intron 5 were ampliﬁed in the control reaction (G). qRT-PCR analysis
of DNA precipitated with anti-SOX9 antiserum shows a 3–4-fold enrichment over DNA precipitated with IgG (n=3) (H). The values shown represent mean values±SEM (standard
error of the mean). AMY, amylase. (A,B,D,E) Scale bar=50 μm.
26 P.A. Seymour et al. / Developmental Biology 323 (2008) 19–30morphometric quantiﬁcation of NGN3+ cells inpancreata from Sox9+/Δpan
embryos and wild-type littermates revealed a ∼50% reduction in
the numbers of NGN3+ cells relative to the pancreatic epithelial cells
at e12.5 (Figs. 5A–C) and e15.5 (Figs. 5D–F). Since a recent study
suggested that Neurog3 regulatory sequences are directly occupied
by SOX9 in the mPAC ductal cell line (Lynn et al., 2007), we directly
tested whether SOX9 binds to the Neurog3 promoter in embryonic
pancreas. Combining CHIP and qRT-PCR analysis in primary
embryonic pancreas tissue, we found that SOX9 was indeed bound
to three of the previously identiﬁed regions in the Neurog3 promoter
(Figs. 5G, H).
These data show that the two-fold reduction in the numbers of
differentiated endocrine cells observed at e18.5 is preceded by a
similar, two-fold decrease in the numbers of endocrine progenitors,
therefore suggesting that the neonatal islet cell defect in Sox9-
haploinsufﬁcient mice is the result of impaired islet cell neogenesis.
Progenitor cell proliferation is Sox9 dosage-sensitive
Our previous analysis of Sox9-deﬁcient pancreata suggested that
relative to the total progenitor cell pool, an excess number of early
endocrine cells differentiate in the absence of SOX9 activity (Seymour
et al., 2007). Therefore, we considered the possibility that the
reduction in NGN3+ cells in Sox9 heterozygous mutant pancreata is a
consequence of precocious depletion of the progenitor cell pool due to
accelerated differentiation at an early developmental time-point.
To assay for premature differentiation in Sox9+/Δpan mice, we
stained pancreata from e12.5 embryos for PDX1 and glucagon, as
glucagon+ cells are the ﬁrst cell type to differentiate in the deve-loping pancreas (Jensen, 2004). In contrast to SOX9-deﬁcient pan-
creata, no difference was seen in the ratio of glucagon+ cells to
undifferentiated PDX1+ progenitors between Sox9-haploinsufﬁcient
and wild-type embryos (Figs. 6A–C). These ﬁndings suggest that the
reduction in NGN3+ endocrine progenitors in Sox9+/Δpan mice is not
caused by premature differentiation of the multipotent progenitor
cell pool. Consistent with this idea, the mRNA levels for Hes1 were
unchanged in e12.5 pancreatic anlagen from Sox9+/Δpan compared to
wild-type embryos (data not shown). Therefore, unlike homozygous
Sox9 deletion (Seymour et al., 2007), Sox9-haploinsufﬁciency does
not affect expression of the key Notch effector Hes1.
To determine whether the requirement for SOX9 in progenitor cell
proliferation is dosage-dependent, we examined proliferation within
the multipotential progenitor cell pool via co-immunoﬂuorescence
analysis for BrdU and PDX1 at e12.5. This analysis revealed mild
reduction of BrdU incorporation by PDX1+ pancreatic progenitors in
Sox9+/Δpan embryos compared with wild-type littermates (Sox9+/Δpan:
13.5±1.76% vs. Sox9+/ﬂox: 18.7±1.58%, n=3; Pb0.05) (Fig. 6E). However,
this reduction in progenitor cell proliferation did not result in an
overt size reduction of the pancreatic buds (Figs. 6A, B). Subsequent
morphometric analysis of the E-cadherin+ epithelial cell area revealed
a slight, but insigniﬁcant reduction in size of both dorsal and ventral
pancreata in Sox9+/Δpan mice (for dorsal bud, mean sectional area=
Sox9+/Δpan: 21,396±3230 μm2 vs. Sox9+/ﬂox: 28,129±4358 μm2, n=3;
for ventral bud, mean sectional area=Sox9+/Δpan: 10,906±2504 μm2
vs. Sox9+/ﬂox: 14,452±4390 μm2, n=3) (Fig. 6D). Unlike cell prolifera-
tion, cell survival was not affected by reduced Sox9 gene dosage, as
TUNEL analysis showed no increase in cell death in Sox9+/Δpan
pancreata (data not shown).
Fig. 6. Sox9-haploinsufﬁciency causes a mild proliferation defect of pancreatic progenitors. The ratio of glucagon+ endocrine cells to PDX1+ pancreatic progenitors is not signiﬁcantly
different between Sox9 heterozygous mutant (Sox9+/Δpan) and wild-type (WT) pancreas (n=3) at e12.5 (A–C). By contrast, the proliferation of PDX1+ progenitors (as measured by
percentage BrdU incorporation of PDX1+ cells) is 25% reduced in Sox9+/Δpan pancreas (n=3) at e12.5 (E). Consequently, mean sectional area of both dorsal and ventral Sox9+/Δpan
pancreata is 25% reduced compared with those of wild-type littermates at e12.5 (D). The values shown represent mean values±SEM (standard error of the mean). E-CAD, E-cadherin;
GLU, glucagon; DP, dorsal pancreas; VP, ventral pancreas; Duo, duodenum; Li, liver. (A, B) Scale bar=50 μm.
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multipotent progenitors require full Sox9 gene dosage. While
progenitor cell proliferation was decreased in Sox9+/Δpan embryos, no
increased cell death or relative increase of early endocrine cells was
observed. These results suggest that the reduction in endocrine
progenitors in Sox9+/Δpan embryos is caused by insufﬁcient generation
of NGN3+ cells from the SOX9+ progenitor cell pool, therefore implying
a dosage-sensitive requirement for SOX9 in initiating cell differentia-
tion. Since SOX9+ progenitors give rise to both endocrine and exocrine
cells, this raises the question of whether reduced SOX9 levels also
affect exocrine differentiation.
Exocrine differentiation is unaffected by reduced Sox9 levels
To investigate whether exocrine differentiation was affected in
Sox9-haploinsufﬁcient embryos, we examined the abundance of
exocrine progenitors in Sox9+/Δpan and wild-type embryos at e12.5.
We performed immunoﬂuorescence analysis for PTF1a (Figs. 7A, B)
and carboxypeptidase A (CPA) (Figs. 7E,F), both of which become
restricted to the distal tips of the branching epithelium around the
time when tip cells commit to an exocrine fate (Zhou et al., 2007).
Compared to wild-type littermates, we observed a small, but insig-
niﬁcant increase in the proportion of the CPA+ and PTF1a+ cells relative
to the epithelial area in Sox9+/Δpan embryos at e12.5 (Figs. 7C, G). This
suggests that reduction in Sox9 dosage in multipotential progenitors
favors adoption of an exocrine fate at the expense of an endocrine
fate. Notably, when expressed as absolute CPA+ or PTF1a+ cell num-
bers to account for the decreased size of the pancreatic epithelium in
Sox9+/Δpan embryos, no difference was seen between Sox9+/Δpan
embryos and wild-type controls (Figs. 7D,H). Consistent with the
observed normal absolute numbers of exocrine-fated progenitors at
e12.5, the size of the exocrine compartment and total organ size was
indistinguishable between Sox9+/Δpan and wild-type pancreata at
e15.5 (Suppl. Fig. 4). This shows that the development of the exocrine
compartment proceeds normally in Sox9+/Δpan embryos and explains
the overall normal organ size at birth despite the initial reduction of
the progenitor cell pool at the pancreatic bud stage. In summary, our
ﬁndings demonstrate a role for SOX9 in pancreatic endocrine cell
differentiation and suggest that SOX9 levels may dictate fate choices
of multipotential pancreatic progenitors.Discussion
While our previous analysis of mice deﬁcient for pancreatic SOX9
revealed a requirement for SOX9 in the maintenance of early
pancreatic progenitor cells (Seymour et al., 2007), the severe early
pancreatic growth arrest precluded an analysis of possible roles for
SOX9 in pancreatic cell differentiation. Here, we demonstrate that
SOX9+ cells are multipotent and give rise to both endocrine and
exocrine cells throughout much of the window of pancreatic
differentiation. By analyzing mice with a 50% reduction in pancreatic
SOX9 protein levels, we further show that SOX9 is required for the
generation of sufﬁcient endocrine progenitors and consequently,
endocrine cells.
SOX9 marks a multipotential pancreatic progenitor cell compartment
Lineage-tracing experiments have proven an informative tool to
determine the developmental potential of different progenitor cell
populations. Cre recombinase-mediated lineage-tracing studies have
shown that all pancreatic cell types, comprising endocrine, acinar
and ductal cells, arise from a common PDX1+/SOX9+ cell pool of the
early pancreatic buds (Akiyama et al., 2005b; Gu et al., 2002). While
these experiments have demonstrated the existence of a multi-
potential progenitor cell pool at the earliest stages of pancreas
development, it has remained unclear whether such a cell
population persists at later developmental time-points. Our previous
ﬁnding that SOX9+ cells are devoid of pro-endocrine, endocrine and
exocrine markers throughout embryogenesis suggested that SOX9
might serve as a marker for a multipotential progenitor cell
compartment. Exploiting the protein stability of GFP, our short-
term lineage-tracing study in Sox9-eGFP mice is the ﬁrst to
demonstrate the persistence of a multipotential pancreatic progeni-
tor cell pool until late in gestation. The presence of GFP in the α-
and β-cell lineages at both e15.5 and e18.5 implies that endocrine
cells arise by a neogenic mechanism from a SOX9+ progenitor cell
pool from the onset of the secondary transition until birth. Notably,
our observation that a portion of NGN3+ cells retained strong GFP
signal, but no SOX9 protein further suggests that committed
endocrine progenitors arise from the SOX9+ epithelial cords. The
presence of GFP in both endocrine cells and amylase+ acinar cells is
Fig. 7. Reduced Sox9 gene dosage does not affect the formation of exocrine-fated cells.
Relative numbers of “proto-acinar” cells, as marked by expression of PTF1a (A–D) or
carboxypeptidase A (CPA) (E–H), are mildly increased in e12.5 Sox9 heterozygous
mutant (Sox9+/Δpan) pancreata compared to wild-type (WT) littermates (n=3). To take
into account the epithelial hypoplasia of Sox9+/Δpan pancreata, the PTF1a+ and CPA+ cell
numbers were normalized to the total DAPI+ pancreatic epithelial cell area (C, G).
However, absolute numbers of PTF1a+ (D) or CPA+ (H) cells per section are unchanged
between Sox9+/Δpan and wild-type pancreata. (A, B) Pancreatic epithelium is highlighted
by a yellow dashed line. The values shown represent mean values±SEM (standard error
of the mean). (A, B, E, F) Scale bar=50 μm.
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acinar cells simultaneously delaminate from the SOX9+ cord/ductal
epithelium, thus demonstrating that the SOX9+ compartment
constitutes a pool of multipotential pancreatic progenitor cells.
Furthermore, our observation of weaker GFP expression in acinar
cells than endocrine cells is consistent with GFP dilution in acinar
cells due to cell division while endocrine cells in contrast are largely
postmitotic. The most striking difference we observed between the
endocrine and exocrine compartment was the retention of GFP in
endocrine, but not in exocrine cells until birth. This implies that
different mechanisms account for expansion of the acinar cell
compartment during early and late embryogenesis. While our data
indicate that acinar cells delaminate from SOX9+ progenitors
immediately after the secondary transition at around e14, the
absence of GFP in exocrine cells in e18.5 embryos suggests that
this mechanism no longer accounts for acinar cell formation in late
embryogenesis. Given the high proliferation rate of acinar cells in
late embryogenesis, it is possible that only a ﬁrst wave of acinar cells
is generated by neogenesis, while cell proliferation ensures subse-
quent expansion of the acinar cell compartment.Pancreatic haploinsufﬁciency for Sox9 in mice phenocopies pancreatic
defects associated with campomelic dysplasia
In the present study, we found that ablation of a single Sox9
gene copy manifests in islet-speciﬁc hypoplasia by birth while
pancreatic exocrine development is unperturbed. Sox9, therefore,
governs pancreatic morphogenesis in a dosage-dependent manner.
This is consistent with a previous report of islet defects associated
with human CD (Piper et al., 2002). Pancreata from neonates
diagnosed with CD were found to exhibit hypoplastic islets with
variable expression of endocrine hormones and reduced expression
of the mature β-cell markers PC1/3 and IAPP (Piper et al., 2002).
Although islet hypoplasia is common to both murine and human
Sox9 haploinsufﬁciency, we observed no loss of mature β-cell
marker expression in mice with heterozygous Sox9 deletion in the
pancreas. This is consistent with normal terminal differentiation of
β-cells in Sox9-haploinsufﬁcient mouse pancreas, suggesting that
the defect responsible for endocrine hypoplasia occurs upstream of
endocrine terminal differentiation, at the initiation of endocrine
development. It is conceivable that such inconsistencies in marker
expression might reﬂect minor differences in programs of
pancreatic differentiation between mouse and human or alterna-
tively, different histological methodologies between the two
studies. Given the highly autolytic nature of the pancreas, and
more challenging nature of human tissue collection at autopsy, it
is also possible that discrepancies between our ﬁndings and those
of Piper et al. (2002) might be attributable to differences in tissue
preservation.
Interestingly, not all phenotypic aspects of the CD syndrome are
observed in Sox9-haploinsufﬁcient mice. Although for example, the
skeletal malformations characteristic of CD are phenocopied in Sox9
heterozygous mutant mice (Bi et al., 2001), the XY sex reversal
associated with the disorder, is not. Instead, complete sex reversal in
mice requires the inactivation of both Sox9 alleles (Barrionuevo et al.,
2006). Thus, sensitivity of organ development to Sox9 gene dosage
appears to differ for certain organs between mice and humans.
However, despite the minor difference in β-cell marker expression,
the Sox9-haploinsufﬁcient pancreatic phenotype in mouse and
humans is strikingly similar. This, in conjunction with the highly
conserved pattern of Sox9 expression in the embryonic mouse and
human pancreas (Piper et al., 2002; Seymour et al., 2007) strongly
indicates a functionally equivalent role for SOX9 in pancreas
development in humans and mice. Therefore, insights gained in
mice into how SOX9 regulates the pancreatic differentiation program
should be applicable in the development of cell-based therapies for
type 1 diabetes in humans.
Formation of endocrine progenitors is sensitive to Sox9 gene dosage
Despite an initial 25% reduction in size at e12.5, the Sox9-haplo-
insufﬁcient pancreas attains wild-type-equivalent organ size by
birth. Reﬂecting the normal organ size, the exocrine compartment
was unaffected in Sox9+/Δpan mice, while islet size was signiﬁcantly
reduced at the end of gestation. One possible explanation for the
reduced islet size in neonatal mice is that it is a direct consequence
of the diminished progenitor cell pool at the early pancreatic bud
stage. However, such depletion of early progenitors will initially not
only affect endocrine cell mass, but also the size of the exocrine
compartment. In contrast to this prediction, we found absolute
numbers of exocrine-fated cells to be normal in Sox9-haploinsufﬁ-
cient embryos despite the size reduction of the pancreatic buds.
Furthermore, at e15.5, when the exocrine compartment has just
begun to form, overall acinar cell mass was similar in Sox9+/Δpan and
wild-type embryos. These ﬁndings argue that the islet-speciﬁc defect
in Sox9+/Δpan embryos is not caused by a general reduction in
pancreatic progenitors, but that Sox9 plays a speciﬁc role in initiating
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the reduction of all major endocrine cell types in Sox9+/Δpan mice
was preceded by a 50% reduction in NGN3+ cells throughout the
window of major cell differentiation. Thus, our analysis of Sox9-
haploinsufﬁcient embryos reveals a novel role for Sox9 in initiating
endocrine cell differentiation from an undifferentiated multipoten-
tial progenitor cell epithelium. Whether SOX9 directly regulates
Neurog3 gene expression is currently still unclear. While this and
another study (Lynn et al., 2007) suggest that Neurog3 regulatory
sequences are occupied by SOX9, activation of endogenous
Neurog3 transcription by SOX9 remains to be demonstrated.
This raises the question of whether SOX9 is speciﬁcally required for
the speciﬁcation of the endocrine lineage or whether it also plays a
role in exocrine cell development. In support of the idea that Sox9
dosage determines cell fate assignment in multipotential progenitors,
we observed a modest increase in exocrine progenitors relative to the
overall diminished progenitor cell pool in Sox9-haploinsufﬁcient
embryos. As a net result, the absolute numbers of exocrine progenitors
were similar in Sox9+/Δpan and control embryos. Since exocrine cells
account for the majority of the pancreatic mass at later developmental
time-points, the normal size of the exocrine progenitor cell pool
explains the normal organ size at birth. Our ﬁndings suggest that a
50% reduction of SOX9 levels in pancreatic progenitor cells slightly
favors their differentiation towards an exocrine fate. Temporally
controlled deletion of Sox9 during the time window of exocrine cell
fate speciﬁcation will be required to fully address the role of Sox9 in
exocrine cell development.
Our ﬁnding that reduced SOX9 levels affect pancreatic cell fate
speciﬁcation illustrates the necessity to tightly control transcription
factor levels during development. Notably, intracellular SOX9 protein
levels are not only controlled by gene dosage, but are also post-
translationally regulated by the ubiquitin-proteasome proteolytic
system (Akiyama et al., 2005a). The paradigm that transcription
factors regulate commitment to speciﬁc cell fates at distinct protein
levels extends beyond SOX9 and has also been demonstrated for other
regulators of stem cell maintenance, such as OCT3/4, Nanog and SOX2
(Kopp et al., 2008; Mitsui et al., 2003; Niwa et al., 2000; Taranova et
al., 2006). For example, high levels of OCT3/4 have been shown to
induce differentiation of mesoderm and endoderm from embryonic
stem cells, while low concentrations induce trophectoderm (Niwa et
al., 2000). If applied to the embryonic pancreas, it is possible that
SOX9 activates different target genes at distinct protein thresholds.
Presumably, a 50% reduction in SOX9 protein levels activates Ngn3
expression in a sub-optimal manner, thereby reducing the probability
that multipotential progenitors will adopt an endocrine fate. At a
molecular level, activation of different target genes at distinct protein
thresholds could be explained by a differential requirement of target
gene promoters for monomeric or dimeric SOX9 binding. For
example, SOX9 dimerization is required for target gene activation in
chondrogenesis but not in sex determination (Bernard et al., 2003).
Since SOX9 monomers and dimers form at distinct protein thresholds
(Sock et al., 2003), a reduction in protein levels will exert differential
effects on the expression of individual target genes. This molecular
mechanism may contribute to the wide spectrum of phenotypic
alterations seen in different CD individuals and may also prove
relevant for differential target gene activation during pancreas
development.
In summary, this study provides the ﬁrst evidence that the
SOX9+ epithelial cords in the developing pancreas represent a
compartment of multipotential pancreatic progenitors that gives
rise to endocrine and exocrine cell lineages. Moreover, our analysis
of heterozygous Sox9-deﬁcient mice uncovers a novel role for Sox9
in the initiation of endocrine development. Future studies will
address whether Sox9 has a speciﬁc role in endocrine cell speci-
ﬁcation or whether it speciﬁes different fates at distinct protein
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